Thea Laboratoires groupe: The latest figures, news and market research on Thea Laboratoires groupe

Turnover: 865 million EUR (2022)

Country: France

Théa is an independent pharmaceutical laboratory owned by the Chibret family, specializing in the research, development and marketing of ophthalmic products.
Founded 28 years ago, Théa is today Europe's leading independent ophthalmology pharmaceutical group.
Headquartered in Clermont-Ferrand, Théa has more than 34 subsidiaries and offices in Europe, Russia, North and South America and the Maghreb.
More than 1,700 employees and products available in over 75 countries worldwide.
An independent, family-owned group

Théa laboratory expands to La Rochelle 25/07/2023

The Théa laboratory is building a new plant to produce ophthalmic cataract inserts.
The plant will meet a 20% to 30% increase in demand.
Sales of the ophthalmic insert are increasing, as it is used in around 60% of cataract operations.
The Théa laboratory has been present in the United States for three years, achieving sales of $40 million thanks to the purchase of a Swiss company. Between 2021 and 2022, Théa's sales in the U.S. have increased by 140 million euros.
Théa has 35 subsidiaries and offices in Europe, North and South America, North Africa and the Middle East, employing over 1,600 people.
Théa products are available in 75 countries.
In 2022, Théa recorded sales of 865 million euros.
Théa's sales forecast for this year is 920 million euros.

Other companies mentioned: